NCT04041310 — Nouscom NOUS-209 neoantigen vaccine trial
Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors
NOUS-209, Nouscom — microsatellite-unstable solid tumors, Phase 1/2
Registry record
| Registry ID | NCT04041310 ↗ |
|---|---|
| Lead sponsor | Nouscom SRL |
| Collaborators | Merck Sharp & Dohme LLC |
| Phase | Phase 1/2 |
| Status | Active Not Recruiting |
| Indication | Solid Tumor, Adult |
| Enrollment | 115 participants (target) |
| Start date | 2019-10-21 |
| Primary completion | 2026-10-30 (est.) |
| Last registry update | 13 Feb 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT04041310), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT04041310?
NCT04041310 (Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors) is registered on ClinicalTrials.gov as Phase 1/2, sponsored by Nouscom SRL.
Is NCT04041310 recruiting?
As of the 2026-02-13 registry update, NCT04041310 is listed as "Active Not Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT04041310?
The lead sponsor is Nouscom SRL. Collaborators: Merck Sharp & Dohme LLC.
What condition does NCT04041310 study?
The registered condition is Solid Tumor, Adult. Primary completion is listed as 2026-10-30 (estimated).
Are results available for NCT04041310?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT04041310.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.